SCHEMBL2808932

SCHEMBL2808932

COc1c(O)cc(C=O)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 1/20 0.54
ALDH1A1 P00352 7/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
GAA P10253 2/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
ALPG P10696 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
AOX1 Q06278 1/20 0.49
TDP1 Q9NUW8 2/20 0.44
TRIM24 O15164 1/20 0.44
HPGD P15428 1/20 0.44
ALDH5A1 P51649 1/20 0.44
ABAT P80404 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5155052 0.86 ALDH1A1 (0.57) ALDH1A1AOX1TDP1TRIM24HPGD
SCHEMBL2391793 0.86 ALDH1A1 (0.46) TPMTALDH1A1KMT2AMEN1GAA
SCHEMBL29361496 0.79 ALDH1A1 (0.59) TPMTALDH1A1GAALMNAMAPT
SCHEMBL6291227 0.79 SRC (0.53) ALDH1A1AOX1TDP1TRIM24HPGD
SCHEMBL3637463 0.79 CA1 (0.55) ALDH1A1AOX1TDP1TRIM24HPGD
SCHEMBL1050289 0.79 ALDH1A1 (0.59) TPMTALDH1A1GAALMNAMAPT
SCHEMBL524215 0.79 KMT2A (0.55) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL1159670 0.78 TUBB1 (0.49) ALDH1A1AOX1TDP1TRIM24HPGD
SCHEMBL16411026 0.78 KMT2A (0.41) TPMTALDH1A1KMT2AGAAMAPT
SCHEMBL2807788 0.78 TPMT (0.54) TPMTALDH1A1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240130988-A1 Use of stilbene compounds in the preparation of anti-tumor drugs GUANGZHOU ANHAO PHARMACEUTICAL TECHNOLOGY CO LTD. (CN) 2024-04-25 US disclosed
EP-4342463-A1 STILBENE COMPOUNDS FOR USE IN THE TREATMENT OF TUMOUR AND EYE DISEASES Guangzhou AnHao Pharmaceutical Technology Co., Ltd. (CN) 2024-03-27 EP disclosed
CN-115444841-B Application of stilbene compounds in preparation of antitumor drugs 广州安好医药科技有限公司 2023-05-12 CN disclosed
CN-115444841-A Application of stilbene compound in preparation of antitumor drugs 广州安好医药科技有限公司 2022-12-09 CN disclosed
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
CN-101679324-B Morpholine derivatives MITSUBISHI TANABE PHARMA CORP 2012-10-03 CN disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
EP-2168952-A1 MORPHOLINE DERIVATIVE Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed
CN-101679324-A Morpholine derivatives MITSUBISHI TANABE PHARMA CORP 2010-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 TPMT 1440/4885ALDH1A1 2202/4885KMT2A 1278/4885
US-20240130988-A1 Use of stilbene compounds in the preparation of anti-tumor drugs CD4, CD81, NFATC1 TPMT 1434/4885ALDH1A1 1799/4885KMT2A 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.